Clinical trials · Kansas
Hormone Receptor Positive Breast Carcinoma clinical trials in Kansas
We’re tracking 10 recruiting hormone receptor positive breast carcinoma studies with a site in Kansas — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Kansas
- NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Kansas City, KansasAges 18 years+ - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Fairway, KansasAges 18 years+ - NCT07020117RecruitingPhase 1
Study of AKY-1189 for advanced solid tumors
This trial tests a new radioactive drug, AKY-1189, for people with solid tumors that have spread or cannot be removed. It may help if other treatments have stopped working.
Westwood, KansasAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Fairway, KansasAges 19 years+ - NCT06184750RecruitingPhase 2
Finding the best tamoxifen dose to lower breast cancer risk
This trial tests different doses of tamoxifen to find the best one for lowering breast cancer risk in premenopausal women. It aims to see if a lower dose works as well as the standard dose with fewer side effects.
Kansas City, KansasAges 18–55 - NCT06058377RecruitingPhase 3
Adding immunotherapy to chemo for stage II-III breast cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).
Hays, KansasAges 18 years+ - NCT04553770RecruitingPhase 2
Trastuzumab deruxtecan with or without anastrozole for early breast cancer
This Phase 2 study tests whether trastuzumab deruxtecan alone or combined with anastrozole can control early-stage breast cancer that is HER2-low and hormone-receptor positive. It aims to improve outcomes after initial surgical treatment by targeting cancer cells that may have low levels of HER2.
Wichita, KansasAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study of rinatabart sesutecan for advanced solid tumors
This trial tests an investigational drug called rinatabart sesutecan (also known as Rina-S) for people with advanced solid tumors, including ovarian, endometrial, lung, breast, and other cancers. The drug is designed to target and kill cancer cells, and the study aims to see if it is safe and effective.
Westwood, KansasAges 18 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Pittsburg, KansasAges 18–60 - NCT04852887RecruitingPhase 3
Testing shorter breast radiation after low-risk hormone breast cancer
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
Wichita, KansasAges 50–70
Where these studies are running in Kansas
Institutions with a site for the recruiting hormone receptor positive breast carcinoma studies listed above.
- University of Kansas Cancer Center · 5 studies
- The University of Kansas Cancer Center - Olathe · 4 studies
- University of Kansas Cancer Center-Overland Park · 4 studies
- University of Kansas Health System Saint Francis Campus · 4 studies
- University of Kansas Hospital-Indian Creek Campus · 4 studies
- University of Kansas Hospital-Westwood Cancer Center · 4 studies
- Salina Regional Health Center · 3 studies
- HaysMed · 2 studies
What taking part in a hormone receptor positive breast carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Hormone Receptor Positive Breast Carcinoma trials in other states
Common questions
- Are there hormone receptor positive breast carcinoma clinical trials in Kansas?
- Yes. We're currently tracking 10 recruiting hormone receptor positive breast carcinoma studies with a site in Kansas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a hormone receptor positive breast carcinoma study in Kansas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Kansas to take part?
- Not necessarily. These studies have a site in Kansas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a hormone receptor positive breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New hormone receptor positive breast carcinoma studies open in Kansas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.